What are the typical clinical features, acute treatment (intravenous immunoglobulin or plasma exchange), supportive care, and prognosis for an adult with Guillain‑Barré syndrome?

Guillain-Barré Syndrome: Clinical Features, Treatment, and Prognosis

Clinical Presentation

Guillain-Barré syndrome presents with rapidly progressive bilateral ascending weakness starting in the legs and spreading to the arms and cranial muscles over days to 4 weeks (typically less than 2 weeks), accompanied by diminished or absent reflexes. 1, 2

Key Diagnostic Features

• Bilateral ascending weakness is the hallmark, typically beginning distally in the legs and progressing proximally to involve arms, trunk, and cranial nerves 1, 2
• Areflexia or hyporeflexia develops early, usually starting in the lower limbs 1
• Distal paresthesias or sensory loss often precede or accompany the weakness 1
• Preceding infection within 6 weeks occurs in approximately two-thirds of patients; Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and Mycoplasma pneumoniae are the most common triggers 1, 2, 3
• Back and limb pain affects approximately two-thirds of patients early in the disease course and can be muscular, radicular, or neuropathic 1

Cranial Nerve and Autonomic Involvement

• Bilateral facial palsy is the most frequently affected cranial nerve manifestation due to the facial nerve's extensive myelin coverage and long intracranial course 1
• Dysautonomia is common and includes blood pressure or heart rate instability, pupillary dysfunction, and bowel or bladder dysfunction 1, 2
• Dysphagia and dysarthria may develop, requiring assessment of swallowing and coughing ability to identify aspiration risk 1

Clinical Variants

• Classic sensorimotor GBS (30–85% of cases): rapidly progressive symmetrical weakness with sensory signs and absent reflexes 1
• Pure motor variant (5–70% of cases): motor weakness without sensory signs; reflexes may remain normal or become exaggerated in the AMAN subtype, which can delay recognition 1
• Miller Fisher syndrome (5–25% of cases): characterized by ophthalmoplegia, ataxia, and areflexia 1

---

Immediate Assessment and Life-Threatening Complications

Immediately assess respiratory function and autonomic stability at presentation, as approximately 20% of patients develop respiratory failure requiring mechanical ventilation, which can occur rapidly and sometimes without obvious dyspnea. 1, 2

Respiratory Monitoring

• Measure vital capacity, negative inspiratory force (NIF), and maximum inspiratory/expiratory pressures at presentation and serially 1
• Apply the "20/30/40 rule": patient is at risk of respiratory failure if vital capacity <20 mL/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 1, 2
• Single breath count ≤19 predicts need for mechanical ventilation 1

Cardiovascular Monitoring

• Perform electrocardiography and continuously monitor heart rate and blood pressure for arrhythmias and blood pressure instability, as autonomic dysfunction contributes to the 3–10% mortality rate 1, 2

Admission Criteria

• Admit patients with Grade 3–4 disease (severe weakness limiting self-care, dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms) to an inpatient unit capable of rapid ICU transfer 1
• Even patients with Grade 2 (moderate) disease require neurology consultation and close monitoring 1

---

Diagnostic Workup

Obtain an immediate neurology consultation for every patient with suspected GBS; do not delay treatment while awaiting confirmatory test results. 1

Cerebrospinal Fluid Analysis

• Perform lumbar puncture to assess for albumino-cytological dissociation (elevated protein with normal cell count) 1, 2, 4
• Do not dismiss GBS based on normal CSF protein in the first week, as this finding may be absent early in the disease course 1
• Marked CSF pleocytosis (significant white cell elevation) should prompt reconsideration of the diagnosis 1

Electrodiagnostic Studies

• Conduct nerve conduction studies and EMG to support the diagnosis and classify the neuropathy pattern (demyelinating vs. axonal) 1, 2, 4
• Look for the "sural sparing pattern": normal sural sensory nerve action potential with abnormal median/ulnar responses, which is typical for GBS 1
• Electrodiagnostic studies may be normal when performed within 1 week of symptom onset; repeat testing in 2–3 weeks if clinical suspicion remains high 1

Additional Testing

• Order complete blood count, glucose, electrolytes, kidney function, and liver enzymes to exclude metabolic or electrolyte dysfunction as causes of weakness 1
• Serum creatine kinase (CK) may be elevated, suggesting muscle involvement, but normal levels do not rule out GBS 1
• MRI of spine with contrast should be obtained to exclude compressive lesions and assess for nerve root enhancement 1
• Serum antiganglioside antibody testing (e.g., anti-GQ1b) should be considered when Miller Fisher syndrome is suspected, but do not delay treatment while awaiting results 1

---

Acute Treatment

Initiate intravenous immunoglobulin (IVIg) 0.4 g/kg daily for 5 consecutive days (total dose 2 g/kg) in patients unable to walk unaided within 2–4 weeks of symptom onset. 1, 2, 4

First-Line Immunotherapy Options

• IVIg 0.4 g/kg/day for 5 days is the preferred first-line therapy because it is easier to administer, more widely available, achieves higher treatment-completion rates, and requires no special equipment or vascular access 1, 4
• Plasma exchange (200–250 mL/kg over 4–5 sessions) is an equally effective alternative when initiated within 4 weeks of symptom onset 1, 4, 5, 6
• IVIg and plasma exchange have equivalent efficacy in severe GBS; the difference between them is so small that a 0.5 grade difference was excluded at the 95% confidence level 5
• Sequential use of plasma exchange followed by IVIg (or vice versa) is not recommended, as combination therapy does not confer a significant advantage 1, 4, 5

Treatment Response and Complications

• Approximately 40% of patients do not improve in the first 4 weeks following treatment; this does not necessarily mean treatment failed, as progression might have been worse without therapy 1
• Treatment-related fluctuations (TRFs) occur in 6–10% of patients, defined as disease progression within 2 months after initial improvement or stabilization 1, 4
• Repeating a full course of IVIg or plasma exchange is common practice for TRFs, although high-quality evidence supporting this approach is lacking 1
• Consider changing the diagnosis to acute-onset CIDP if progression continues after 8 weeks from onset or if the patient has three or more TRFs; this occurs in approximately 5% of patients initially diagnosed with GBS 1, 4

Treatments NOT Recommended

• Corticosteroids alone are NOT recommended for idiopathic GBS 1, 3, 4
• A second IVIg course is not recommended in GBS patients with a poor prognosis 4

---

Supportive Care

Comprehensive supportive care is critical for patient outcomes and includes pain management, prevention of complications, and psychological support. 1

Pain Management

• Use gabapentinoids (gabapentin or pregabalin) or duloxetine for neuropathic pain; these are weakly recommended and can be started concurrently with IVIg without drug interaction 1, 4
• Tricyclic antidepressants or carbamazepine are alternative options for neuropathic pain 1, 4
• Encourage mobilization for muscle pain and arthralgia 1

Monitoring and Complication Prevention

• Perform daily neurologic examinations to track disease progression 1
• Conduct frequent pulmonary function testing with serial vital capacity and NIF measurements 1
• Monitor for autonomic dysfunction including blood pressure/heart rate instability, pupillary dysfunction, and bowel/bladder dysfunction 1
• Provide standard preventive measures for pressure ulcers, hospital-acquired infections, and deep vein thrombosis 1
• Treat constipation/ileus as needed 1

Medications to Avoid

• Avoid medications that can worsen neuromuscular transmission: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 1, 7

Psychological Support

• Recognize that patients with GBS, even those with complete paralysis, usually have intact consciousness, vision, and hearing 1
• Screen for anxiety, depression, and hallucinations, which are frequent complications 1
• Be mindful of what is said at bedside and explain procedures to reduce anxiety 1

---

Prognosis and Long-Term Outcomes

Approximately 80% of patients regain independent walking ability at 6 months, with recovery continuing for more than 3 years and improvements possible even beyond 5 years. 1, 2, 4, 8

Recovery Timeline

• Disease progression typically reaches maximum disability within 2 weeks of symptom onset 1, 2
• Full recovery can be expected in approximately 90% of cases, although recovery may take up to 2 years in some patients 1
• Functional recovery may continue for several years, with improvements reported beyond 5 years 1

Mortality and Risk Factors

• Mortality is 3–10%, primarily from cardiovascular and respiratory complications occurring in both the acute and recovery phases 1, 2, 3, 4, 8
• Advanced age and severe disease at onset are risk factors for poor outcome 1, 4

Long-Term Sequelae

• Fatigue affects 60–80% of survivors and is a major disabling symptom 1
• Severe pain persists in at least one-third of patients at 1 year and may continue for more than a decade 1
• Recurrence is rare (2–5% of patients) but higher than the general population lifetime risk (0.1%); prior GBS is not a strict contraindication for vaccination 1, 4

---

Rehabilitation

Arrange a rehabilitation program with a rehabilitation specialist, physiotherapist, and occupational therapist as a crucial step toward recovery. 1

• Exercise programs (range-of-motion exercises, stationary cycling, walking, strength training) improve physical fitness, walking ability, and independence in activities of daily living 1
• Monitor exercise intensity to avoid fatigue, which is a major disabling symptom 1

---

Common Pitfalls

• Do not dismiss GBS based on normal CSF protein in the first week or absent sural sparing on early electrodiagnostic studies; repeat testing if clinical suspicion remains high 1
• Bilateral simultaneous facial weakness is extremely rare in Bell's palsy and should immediately raise suspicion for GBS 1
• Do not delay treatment while awaiting antibody test results; treatment should be initiated based on clinical suspicion 1
• Marked persistent asymmetry, bladder dysfunction at onset, or marked CSF pleocytosis should prompt reconsideration of the diagnosis 1